When will Novo Nordisk start selling Wegovy in vials?

Novo Nordisk plans to introduce Wegovy in vial form in the US this year, with subsequent sales in other countries.

Why is Novo Nordisk introducing Wegovy vials?

The introduction of Wegovy vials is a strategic move to compete with Eli Lilly & Co.'s offerings, provide more flexible dosing, and broaden the drug's accessibility to patients.

How are Novo Nordisk's pricing strategies affecting its sales?

Novo Nordisk is aggressively discounting its obesity drugs to gain market share, but these price cuts are expected to negatively impact the company's sales by up to 13% this year.

Home / Business and Economy / Novo Nordisk to Launch Wegovy Vials Amid Price War

Novo Nordisk to Launch Wegovy Vials Amid Price War

12 Feb

•

Summary

Novo Nordisk plans to release Wegovy in vials this year, starting in the US.
The move aims to compete with Eli Lilly's lower-priced vial options.
Novo Nordisk is also cutting prices on its obesity drugs to gain market share.

Novo Nordisk to Launch Wegovy Vials Amid Price War

Novo Nordisk A/S is preparing to launch Wegovy in vial form, a significant step to enhance its competitiveness against rival Eli Lilly & Co. The company intends to introduce these vials in the US this year, with subsequent rollouts in other international markets. This strategic expansion aims to broaden the drug's accessibility and appeal to a wider patient base.

The introduction of vials offers patients more flexible dosing options, a feature that has proven popular with Eli Lilly's offerings. Lilly began selling vials of its weight-loss drug in 2024, a move that also helped alleviate supply shortages. These vials, available through Lilly's direct-to-consumer platform, now constitute a substantial portion of new patients starting weight-loss medications.